[go: up one dir, main page]

WO2009095517A3 - Métodos y composiciones capaces de provocar un silenciamiento post-transcripcional de la expresión génica de forma sinérgica - Google Patents

Métodos y composiciones capaces de provocar un silenciamiento post-transcripcional de la expresión génica de forma sinérgica Download PDF

Info

Publication number
WO2009095517A3
WO2009095517A3 PCT/ES2009/000045 ES2009000045W WO2009095517A3 WO 2009095517 A3 WO2009095517 A3 WO 2009095517A3 ES 2009000045 W ES2009000045 W ES 2009000045W WO 2009095517 A3 WO2009095517 A3 WO 2009095517A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene expression
methods
compositions capable
transcriptional silencing
causing post
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES2009/000045
Other languages
English (en)
French (fr)
Other versions
WO2009095517A2 (es
Inventor
Xabier Abad Lloret
María Purificación FORTES ALONSO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Priority to EP09705069A priority Critical patent/EP2246432A2/en
Priority to CA2713458A priority patent/CA2713458A1/en
Priority to US12/865,046 priority patent/US20110030075A1/en
Priority to MX2010008326A priority patent/MX2010008326A/es
Priority to BRPI0906657-8A priority patent/BRPI0906657A2/pt
Priority to JP2010544739A priority patent/JP2011510647A/ja
Priority to AU2009209571A priority patent/AU2009209571A1/en
Priority to CN2009801118031A priority patent/CN101981189A/zh
Publication of WO2009095517A2 publication Critical patent/WO2009095517A2/es
Publication of WO2009095517A3 publication Critical patent/WO2009095517A3/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se relaciona con composiciones para la inhibición post-transcripcional de la expresión génica mediante el uso combinado de un ARN U1 modificado dirigido contra una región preseleccionada en un pre-ARNm diana y de un agente silenciador de la expresión génica del tipo siRNA, shRNA y/o miRNA, así como al uso de dichas combinaciones para el tratamiento de enfermedades causadas por la sobre-expresión indeseadas de una proteína.
PCT/ES2009/000045 2008-01-29 2009-01-29 Métodos y composiciones capaces de provocar un silenciamiento post-transcripcional de la expresión génica de forma sinérgica Ceased WO2009095517A2 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP09705069A EP2246432A2 (en) 2008-01-29 2009-01-29 Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner
CA2713458A CA2713458A1 (en) 2008-01-29 2009-01-29 Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner
US12/865,046 US20110030075A1 (en) 2008-01-29 2009-01-29 Methods and Compositions Capable of Causing Post-Transcriptional Silencing of Gene Expression in a Synergic Manner
MX2010008326A MX2010008326A (es) 2008-01-29 2009-01-29 Metodo y composiciones capaces de provocar un silenciamiento post-transcripcional de la expresion genica de forma sinergica.
BRPI0906657-8A BRPI0906657A2 (pt) 2008-01-29 2009-01-29 Métodos e composições capazes de causar um silenciamento pós-transcricional da expressão genética de forma sinérgica
JP2010544739A JP2011510647A (ja) 2008-01-29 2009-01-29 遺伝子発現の転写後抑制を相乗的に生じさせることができる方法および組成物
AU2009209571A AU2009209571A1 (en) 2008-01-29 2009-01-29 Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner
CN2009801118031A CN101981189A (zh) 2008-01-29 2009-01-29 能够以协同方式引起基因表达转录后沉默的方法和组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200800222 2008-01-29
ES200800222 2008-01-29

Publications (2)

Publication Number Publication Date
WO2009095517A2 WO2009095517A2 (es) 2009-08-06
WO2009095517A3 true WO2009095517A3 (es) 2009-09-24

Family

ID=40807539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2009/000045 Ceased WO2009095517A2 (es) 2008-01-29 2009-01-29 Métodos y composiciones capaces de provocar un silenciamiento post-transcripcional de la expresión génica de forma sinérgica

Country Status (10)

Country Link
US (1) US20110030075A1 (es)
EP (1) EP2246432A2 (es)
JP (1) JP2011510647A (es)
CN (1) CN101981189A (es)
AU (1) AU2009209571A1 (es)
BR (1) BRPI0906657A2 (es)
CA (1) CA2713458A1 (es)
MX (1) MX2010008326A (es)
RU (1) RU2010136040A (es)
WO (1) WO2009095517A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8907075B2 (en) 2007-03-30 2014-12-09 Samuel Ian Gunderson Compositions and methods for gene silencing
US9441221B2 (en) 2007-03-30 2016-09-13 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
US8343941B2 (en) 2007-03-30 2013-01-01 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
WO2012045894A1 (es) * 2010-10-05 2012-04-12 Proyecto De Biomedicina Cima, S.L. Compuestos y composiciones para el tratamiento de enfermedades debidas a la infección por el virus de la hepatitis b
MX388221B (es) * 2013-04-20 2025-03-19 Res Institute At Nationwide Children´S Hospital ADMINISTRACIÓN DE VIRUS ADENO-ASOCIADO RECOMBINANTE DE CONSTRUCCIONES DE POLINUCLÉOTIDOS U7snRNA DIRIGIDA AL EXÓN 2.
EP2853595A1 (en) * 2013-09-30 2015-04-01 Soluventis GmbH NOTCH 1 specific siRNA molecules
CN107746857B (zh) * 2017-08-07 2021-02-05 中国农业大学 一种抑制基因表达的rna干扰方法
CN108893487A (zh) * 2018-07-19 2018-11-27 中国农业科学院北京畜牧兽医研究所 一种含有C-Myc蛋白融合标签的植物表达质粒载体及其载体的构建方法
CA3132388A1 (en) * 2019-03-08 2020-09-17 Rutgers, The State University Of New Jersey Compositions and methods for treating huntington's disease
CN114159459A (zh) * 2021-12-20 2022-03-11 塔里木大学 miR-26a在制备治疗子宫内膜炎的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082149A1 (en) * 1997-07-28 2003-05-01 Cummings & Lockwood Inhibition of a target messenger rna with a modified u1 small nuclear rna
EP1384784A1 (en) * 2001-03-30 2004-01-28 Instituto Cientifico Y Tecnologico De Navarra, S.A. Method for reversible inhibition of gene expression by modified ribonucleoproteins
WO2008093141A1 (en) * 2007-01-30 2008-08-07 Scottish Crop Research Institute Inhibition of gene expression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP2390328A1 (en) 2001-09-28 2011-11-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
ES2465574T3 (es) 2002-05-03 2014-06-06 Duke University Un método para regular la expresión génica
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
US20080131940A1 (en) 2004-06-25 2008-06-05 Robert Chiu Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
WO2007046703A2 (en) 2005-10-20 2007-04-26 Amsterdam Molecular Therapeutics B.V. Improved aav vectors produced in insect cells
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
US8512981B2 (en) 2006-06-21 2013-08-20 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082149A1 (en) * 1997-07-28 2003-05-01 Cummings & Lockwood Inhibition of a target messenger rna with a modified u1 small nuclear rna
EP1384784A1 (en) * 2001-03-30 2004-01-28 Instituto Cientifico Y Tecnologico De Navarra, S.A. Method for reversible inhibition of gene expression by modified ribonucleoproteins
WO2008093141A1 (en) * 2007-01-30 2008-08-07 Scottish Crop Research Institute Inhibition of gene expression

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ABAD X. ET AL.: "Comparison Between RNAu and RNAi", PROCEEDINGS OF THE 2008 MIAMI WINTER SYMPOSIUM, vol. 19, 2 February 2008 (2008-02-02) - 6 February 2008 (2008-02-06), pages T9, XP002535621, Retrieved from the Internet <URL:http://www.med.miami.edu/mnbws/documents/ABAD.pdf> [retrieved on 20090707] *
ABAD XABI ET AL: "Requirements for gene silencing mediated by U1 snRNA binding to a target sequence", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 36, no. 7, 1 April 2008 (2008-04-01), pages 2338 - 2352, XP002481004, ISSN: 0305-1048, [retrieved on 20080224] *
BECKLEY S A ET AL: "Reduction of target gene expression by a modified U1 snRNA", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 21, no. 8, 1 April 2001 (2001-04-01), pages 2815 - 2825, XP002481002, ISSN: 0270-7306 *
FORTES PURI ET AL: "Inhibiting expression of specific genes in mammalian cells with 5' end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC., US, vol. 100, no. 14, 8 July 2003 (2003-07-08), pages 8264 - 8269, XP002481001, ISSN: 0027-8424 *
LIU PENG ET AL: "Modified U1 snRNA suppresses expression of a targeted endogenous RNA by inhibiting polyadenylation of the transcript", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 32, no. 4, 1 January 2004 (2004-01-01), pages 1512 - 1517, XP002481003, ISSN: 0305-1048 *
SAJIC R ET AL: "Use of modified U1 snRNAs to inhibit HIV-1 replication.", NUCLEIC ACIDS RESEARCH 2007, vol. 35, no. 1, 2007, pages 247 - 255, XP002535620, ISSN: 1362-4962 *

Also Published As

Publication number Publication date
JP2011510647A (ja) 2011-04-07
MX2010008326A (es) 2010-08-18
CA2713458A1 (en) 2009-08-06
CN101981189A (zh) 2011-02-23
US20110030075A1 (en) 2011-02-03
BRPI0906657A2 (pt) 2015-07-14
AU2009209571A1 (en) 2009-08-06
WO2009095517A2 (es) 2009-08-06
EP2246432A2 (en) 2010-11-03
RU2010136040A (ru) 2012-03-10

Similar Documents

Publication Publication Date Title
WO2009095517A3 (es) Métodos y composiciones capaces de provocar un silenciamiento post-transcripcional de la expresión génica de forma sinérgica
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
IL215682A0 (en) Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2013074974A3 (en) Modified rnai agents
WO2010056737A3 (en) Methods and compositions involving mirnas in cancer stem cells
WO2008152131A3 (en) Rnai inhibition of alpha-enac expression
WO2014022739A3 (en) Modified rnai agents
WO2010111653A3 (en) Modulating ires-mediated translation
WO2011083150A3 (en) Obesity small molecules
WO2007053696A3 (en) Rnai inhibition of influenza virus replication
WO2009045356A3 (en) Microrna compositions in the treatment of vegf-mediated disorders
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
PT3363415T (pt) Fragmentação curva de tecido por laser fotodisruptivo
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
WO2009134487A3 (en) Optimized methods for delivery of dsrna targeting the pcsk9 gene
WO2007092182A3 (en) Rna interference agents for therapeutic use
WO2010129861A3 (en) Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
WO2009048932A3 (en) Methods to regulate mirna processing by targeting lin-28
WO2012054862A9 (en) Agents, compositions, and methods for treating pruritis and related skin conditions
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011079261A3 (en) Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
WO2011150007A3 (en) Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
WO2010032011A3 (en) Anti-fungal therapy
IL217944B (en) Kurroa picrorhiza extract for the prevention, mitigation and treatment of diseases caused by DNA-based viruses in humans

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980111803.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09705069

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2713458

Country of ref document: CA

Ref document number: 2010544739

Country of ref document: JP

Ref document number: MX/A/2010/008326

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2787/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009209571

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009705069

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010136040

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2009209571

Country of ref document: AU

Date of ref document: 20090129

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12865046

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0906657

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100729